Simcere Pharmaceutical Forecasts Slight Increase in 2024 Profit
I'm PortAI, I can summarize articles.
Simcere Pharmaceutical's attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the Hong Kong Stock Exchange. Revenue is also forecast to inch up 0.2% to 0.6% to between 6.62 billion yuan and 6.65 billion yuan. The drug company plans to release fiscal 2024 results in late March.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments